Assertio Therapeutics (ASRT) Misses Q4 EPS by 99c

Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($1.06), $0.99 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $28.36 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
• DAP Introduces Gaps & Cracks High Density Foam with HydroAction Polyurethane
• Jonathan Korngold resigns from Bumble board amid Blackstone departure